These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

957 related items for PubMed ID: 8036284

  • 1. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK.
    Regul Pept; 1994 Apr 14; 51(1):63-74. PubMed ID: 8036284
    [Abstract] [Full Text] [Related]

  • 2. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    J Clin Endocrinol Metab; 1993 Apr 14; 76(4):912-7. PubMed ID: 8473405
    [Abstract] [Full Text] [Related]

  • 3. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Regul Pept; 2003 Jul 15; 114(2-3):115-21. PubMed ID: 12832099
    [Abstract] [Full Text] [Related]

  • 4. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.
    J Clin Invest; 1993 Jan 15; 91(1):301-7. PubMed ID: 8423228
    [Abstract] [Full Text] [Related]

  • 5. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Diabetologia; 2002 Aug 15; 45(8):1111-9. PubMed ID: 12189441
    [Abstract] [Full Text] [Related]

  • 6. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.
    J Clin Endocrinol Metab; 2003 Oct 15; 88(10):4897-903. PubMed ID: 14557471
    [Abstract] [Full Text] [Related]

  • 7. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
    Fehmann HC, Göke R, Göke B, Bächle R, Wagner B, Arnold R.
    Biochim Biophys Acta; 1991 Feb 19; 1091(3):356-63. PubMed ID: 1705823
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
    Suzuki S, Kawai K, Ohashi S, Mukai H, Murayama Y, Yamashita K.
    Diabetes; 1990 Nov 19; 39(11):1320-5. PubMed ID: 2146178
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.
    Diabetes; 1996 Nov 19; 45(11):1524-30. PubMed ID: 8866556
    [Abstract] [Full Text] [Related]

  • 14. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T, Fujita Y, Takeda Y, Honjo J, Sakagami H, Kitsunai H, Takiyama Y, Abiko A, Makino Y, Kieffer TJ, Haneda M.
    Mol Metab; 2017 Feb 19; 6(2):226-231. PubMed ID: 28180064
    [Abstract] [Full Text] [Related]

  • 15. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.
    J Clin Endocrinol Metab; 2003 Jun 19; 88(6):2706-13. PubMed ID: 12788877
    [Abstract] [Full Text] [Related]

  • 16. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.
    Fukase N, Manaka H, Sugiyama K, Takahashi H, Igarashi M, Daimon M, Yamatani K, Tominaga M, Sasaki H.
    Acta Diabetol; 1995 Oct 19; 32(3):165-9. PubMed ID: 8590785
    [Abstract] [Full Text] [Related]

  • 17. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    Digestion; 1992 Oct 19; 52(3-4):214-21. PubMed ID: 1459356
    [Abstract] [Full Text] [Related]

  • 18. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
    Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB.
    Eur J Endocrinol; 1996 Oct 19; 135(4):425-32. PubMed ID: 8921824
    [Abstract] [Full Text] [Related]

  • 19. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
    Christensen MB.
    Dan Med J; 2016 Apr 19; 63(4):. PubMed ID: 27034187
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.